RSQCX
Price
$15.23
Change
+$0.13 (+0.86%)
Updated
Jun 9 closing price
Net Assets
471.86M
VSCAX
Price
$32.06
Change
-$0.23 (-0.71%)
Updated
Jun 9 closing price
Net Assets
11.28B
Interact to see
Advertisement

RSQCX vs VSCAX

Header iconRSQCX vs VSCAX Comparison
Open Charts RSQCX vs VSCAXBanner chart's image
RSQCX vs VSCAX Comparison Chart in %
View a ticker or compare two or three
VS
RSQCX vs. VSCAX commentary
Jun 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RSQCX is a Buy and VSCAX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCAX has more cash in the bank: 11.3B vs. RSQCX (472M). RSQCX pays higher dividends than VSCAX: RSQCX (1.32) vs VSCAX (0.20). RSQCX was incepted earlier than VSCAX: RSQCX (23 years) vs VSCAX (27 years). RSQCX (2.45) is less costly to investors than VSCAX (1.10). VSCAX is a more actively managed with annual turnover of: 52.00 vs. RSQCX (12.00). VSCAX has a lower initial minimum investment than RSQCX: VSCAX (1000) vs RSQCX (2000). VSCAX annual gain was more profitable for investors over the last year : 40.93 vs. RSQCX (20.62). VSCAX return over 5 years is better than : 51.94 vs. RSQCX (-17.94).
RSQCXVSCAXRSQCX / VSCAX
Total Expense Ratio2.241.10204%
Annual Report Gross Expense Ratio2.451.10223%
Fund Existence23 years27 years-
Gain YTD20.01627.57873%
Front LoadN/A6%-
Min. Initial Investment20001000200%
Min. Initial Investment IRAN/AN/A-
Net Assets472M11.3B4%
Annual Yield % from dividends1.320.20649%
Returns for 1 year20.6240.9350%
Returns for 3 years2.3982.333%
Returns for 5 years-17.9451.94-35%
Returns for 10 years-11.34106.64-11%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CBOE290.6010.28
+3.67%
Cboe Global Markets
DOUG1.720.01
+0.58%
Douglas Elliman
CPRX31.330.05
+0.18%
Catalyst Pharmaceuticals
ESPR3.14-0.01
-0.32%
Esperion Therapeutics
INTS3.71-0.07
-1.85%
Intensity Therapeutics Inc.